Novartis AG, AstraZeneca, and Amgen Inc., Dominated the Global Acute Coronary Syndrome Market in 2021

Global Acute Coronary Syndrome Market is expected to grow with the CAGR of 5.2% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below:

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-acute-coronary-syndrome-market

Global acute coronary syndrome market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favorable market scenario.   

The major players dealing in global acute coronary syndrome market are introducing a wide range of products along with adopting strategic initiatives such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced service portfolio.

  • In October 2021, Novartis AG expanded a new digital healthcare solution across chronic heart disease management. Co-developed with China’s internet multinational Tencent, together with leading Chinese medical organizations, the digital healthcare solution is now broadening its scope to cardiovascular disease in general – supporting patients from pre-diagnosis to hospital discharge and ongoing at-home disease management. It helps patients with heart failure to easily accommodate disease management into everyday living, alerting them to signs of disease worsening. Patients can then take early action to avoid re-hospitalization, in a country where heart disease is on the rise.

The other key players existing in the market are Novartis AG, AstraZeneca, Amgen Inc, Sanofi, Dr. Reddy’s Laboratories Ltd, Baxter, Pfizer Inc, Merck & Co., Inc, Regeneron Pharmaceuticals Inc, Boehringer Ingelheim International GmbH, Johnson & Johnson Services, Inc, Teva Pharmaceutical Industries Ltd, DAIICHI SANKYO COMPANY, CSL and among others.

Novartis AG

Novartis AG is headquartered in Basel, Switzerland founded in year 1996. The company offers Innovative Medicines and Sandoz. The company focuses on innovating new solutions for various health care challenges. The company has Cancer, Cardiovascular, Renal & Metabolism, Immunology & Dermatology, Ophthalmology, Neuroscience, and Respiratory as a product category and Cardiovascular as the market-focused category.

  • In October 2021, Novartis AG expanded a new digital healthcare solution across chronic heart disease management. Co-developed with China’s internet multinational Tencent, together with leading Chinese medical organizations, the digital healthcare solution is now broadening its scope to cardiovascular disease in general – supporting patients from pre-diagnosis to hospital discharge and ongoing at-home disease management. It helps patients with heart failure to easily accommodate disease management into everyday living, alerting them to signs of disease worsening. Patients can then take early action to avoid re-hospitalization, in a country where heart disease is on the rise.

The company has a presence in the Americas, Asia-Pacific, Europe/Middle East /Africa. The company has various subsidiaries that are Novartis Argentina S.A., Buenos Aires(Argentina), Novartis Australia Pty Ltd, Macquarie Park, NSW(Australia), Novartis Austria GmbH, Vienna(Austria), Novartis Pharma NV, Vilvoorde(Belgium), Sandoz (China) Pharmaceutical (China) among others.

AstraZeneca

AstraZeneca is headquartered in Cambridge, U.K. was founded in the year 1999. The company offers Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology.  Cardiovascular, Renal & Metabolism, Oncology, Infection and Vaccines, Neuroscience, Respiratory and Gastrointestinal as a product category and Cardiovascular, Renal & Metabolism as the market-focused category. The company has presence in North America, Europe, Africa and Asia & Pacific

  • In December 2020, Astra Zeneca announced that the company has acquired Alexion, a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. This helps in accelerating the company’s strategic and financial developments that delivers life-changing medicines for patients.

The company has various subsidiaries that are AstraZeneca Limited (Thailand), AstraZeneca (Wuxi) Trading Co. Ltd (China), AstraZeneca AB (Sweden), AstraZeneca AG (Switzerland), AstraZeneca AS (Norway), among others.

Amgen Inc.

Amgen Inc. is headquartered in California, U.S. was founded in the year 1980. The company offers Human Therapeutics, and Cardiovascular Disease, Oncology, Bone Health, Neuroscience, Nephrology and Inflammation as product category and Cardiovascular Diseases as the market-focused category. The company has presence in North America, Asia Pacific, South America, Europe, Middle East and Africa.

  • In February 2021, Amgen and Plexium, Inc. announced an exclusive, worldwide, multi-year research collaboration and license agreement to identify novel targeted protein degradation therapeutics toward historically challenging drug targets. The multi-year collaboration supports the discovery of novel molecular glue therapeutics leveraging insights from Amgen's expertise in developing multi-specific molecules. Collaborating with Plexium and leveraging their innovative technology to identify molecular glue degraders can help tackle some of the most challenging protein targets to address serious disease.

The company has various subsidiaries that are Amgen (Europe) GmbH Switzerland, Amgen Fremont Inc. (Delaware), Amgen Global Finance B.V. (Netherlands), Amgen GmbH (Germany), Amgen Ilaç Ticaret Limited Şirketi (Turkey), Amgen Manufacturing, Limited (Bermuda), Amgen Research (Munich) GmbH Germany, Amgen Rockville, Inc. (Delaware), Amgen S.A.S. (France).